趋化因子受体4在普通型骨肉瘤中的表达及意义  

Expression and clinical implication of Chemokine receptor 4 in conventional osteosarcoma

作　　者：宫晨[1] 李觅[1] 姚斌[1] 徐飞[1] 任晔[1] 郭风劲[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院骨科,武汉430030

出　　处：《骨科》2012年第3期117-119,共3页ORTHOPAEDICS

基　　金：华中医科大学同济医学院附属同济医院肿瘤侵袭转移教育部重点实验室开放基金(No.2010KF01)

摘　　要：目的探讨趋化因子受体4(chemokine receptor 4,CXCR4)在普通型骨肉瘤中的表达及其临床意义。方法应用免疫组织化学法检测38例普通型骨肉瘤患者肿瘤组织中CXCR4的表达水平,并对其与肿瘤病理学类型、性别和转移的关系进行统计学分析。结果 38例骨肉瘤组织中CXCR4阳性率为50.0%,不同性别和病理学类型的骨肉瘤组织中CXCR4阳性率无显著差异(P>0.05),而有、无转移发生的骨肉瘤组织中CXCR4阳性率分别为38.5%和75.0%,有显著性差异(P<0.05)。结论 CXCR4可作为预测普通型骨肉瘤转移的指标。Objective To investigate the expression and clinical implication of chemokine receptor 4 in conventional os teosarcoma. Methods The expression of chemokine receptor 4 was detected by using immunohistochemistry in 38 cases of con ventional osteosarcoma, and its correlation with gender, histopathological types, metastasis was analyzed. Results The posi tive rate of chemokine receptor 4 in conventional osteosareomas was 50. 0%, and there were no significant differences in posi tive rate of chemokine receptor 4 between males and females, and between different histopathological types. There was signifi cant difference in chemokine receptor 4 positive rate between patients with metastasis and those without metastasis （38. 50% vs. 75.0 %, P〈0. 05）. Conclusion Chemokine receptor 4 might become a predictor of metastasis in conventional osteosarcoma.

关 键 词：骨肉瘤 受体 CXCR4 免疫组织化学 

分 类 号：R738.1[医药卫生—肿瘤]